retatrutide phase 2 trial type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide Severe Obesity Trial Shows

KEY TAKEAWAY: Month 2 is survival mode

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, et al

Retatrutide vs Tirzepatide

In recent years, GLP-1R and its agonists have become a hot research topic and a star drug in the field of diabetes treatment

The 48-week figure comes from the trial design and represents where most participants reach or approach plateau at the 12mg dose